ANIX
MaterialsAnixa Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving ANIX Today?
No stock-specific AI insight has been generated for ANIX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
ANIX News
20 articles- Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TVYahoo Finance·May 1, 2026
- Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine TechnologyYahoo Finance·Apr 29, 2026
- Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual MeetingYahoo Finance·Apr 22, 2026
- Replays from RedChip's Biotech Investor Conference Now AvailableYahoo Finance·Apr 20, 2026
- Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at ConferenceMarketbeat·Apr 15, 2026
- RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech InnovationYahoo Finance·Apr 10, 2026
- Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026Yahoo Finance·Apr 9, 2026
- Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026Yahoo Finance·Apr 7, 2026
- Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy ProgramsYahoo Finance·Apr 6, 2026
- Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP ManufacturingYahoo Finance·Apr 1, 2026
- Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's CancerYahoo Finance·Mar 30, 2026
- Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine ProgressMarketbeat·Mar 13, 2026
- Anixa Biosciences Featured on Water Tower Research Healthcare Happenings PodcastYahoo Finance·Mar 12, 2026
- Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine TechnologyYahoo Finance·Mar 9, 2026
- Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory ProgressYahoo Finance·Mar 2, 2026
- Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 RetreatYahoo Finance·Feb 23, 2026
- Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T AdvanceMarketbeat·Feb 10, 2026
- Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose EscalationYahoo Finance·Feb 9, 2026
- Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn SituationYahoo Finance·Feb 8, 2026
- Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future CommercializationYahoo Finance·Feb 2, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Anixa Biosciences Inc
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.